Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

La Jolla Riquent doesn’t meet endpoint

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

La Jolla's lupus agent Riquent (formerly LJP 394) did not statistically significantly increase length of time to renal flare compared to placebo in a preliminary analysis of a 298-patient Phase III trial. Riquent appeared to be well tolerated; patients were treated up to 92 weeks (median of 46 weeks). The estimated median time to renal flare, the primary endpoint, was 123 months on the Riquent arm and 89 months on the placebo arm. Renal flares occurred in 17 (12%) Riquent patients and 24 (16%) placebo patients. "Changes in medical practice may have resulted in fewer renal flares because patients were being treated before a renal flare could have been observed or documented," La Jolla maintains. In a combined analysis of renal and/or major SLE flares, there were 33 (26%) events in Riquent patients and 51 (33%) in placebo patients. Riquent did yield a significant reduction in antibodies to double-stranded DNA, which is its intended pharmacologic effect. The company continues to analyze study result
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS002197

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel